These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35700341)

  • 1. Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027: Confirmation of Target Engagement and Selection of Phase 2 Dose in Dementia With Lewy Bodies Trial.
    Landry IS; Aluri J; Schuck E; Ino M; Horie K; Boyd P; Reyderman L; Lai R
    Alzheimer Dis Assoc Disord; 2022 Jul-Sep 01; 36(3):200-207. PubMed ID: 35700341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E2027 Cardiac Safety Evaluation With Concentration-Response Modeling of ECG Data to Inform Dose Selection in Studies in Patients With Dementia With Lewy Bodies.
    Landry IS; Boyd P; Aluri J; Darpo B; Xue H; Brown R; Reyderman L; Lai R
    Alzheimer Dis Assoc Disord; 2022 Jul-Sep 01; 36(3):208-214. PubMed ID: 35622456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, Pharmacokinetics, and Pharmacodynamics of TD-0714, a Novel Potent Neprilysin Inhibitor in Healthy Adult and Elderly Subjects.
    Kanodia J; Lo A; Baldwin RM; Colley K; Zhou K; Bourdet DL
    Clin Transl Sci; 2020 Nov; 13(6):1307-1315. PubMed ID: 32506827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832.
    Dawson R; Diacon AH; Narunsky K; De Jager VR; Stinson KW; Zhang X; Liu Y; Hafkin J
    Antimicrob Agents Chemother; 2023 Jun; 67(6):e0147722. PubMed ID: 37219453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
    Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
    Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants.
    Hincelin-Mery A; Nicolas X; Cantalloube C; Pomponio R; Lewanczyk P; Benamor M; Ofengeim D; Krupka E; Hsiao-Nakamoto J; Eastenson A; Atassi N
    Clin Transl Sci; 2024 Jan; 17(1):e13690. PubMed ID: 38010108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjects.
    Shiozaki T; Ueno T; Nagashima H; Yamahira N; Hiraoka M; Eley T; Bifano M; Bertz RJ
    Int J Clin Pharmacol Ther; 2015 Apr; 53(4):292-302. PubMed ID: 25740262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies.
    Desai A; Benner L; Wu R; Gertsik L; Uz T; Marek GJ; Zhu T
    Clin Pharmacokinet; 2021 Jan; 60(1):79-88. PubMed ID: 32533536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials.
    van der Aar E; Desrivot J; Dupont S; Heckmann B; Fieuw A; Stutvoet S; Fagard L; Van de Wal K; Helmer E
    J Clin Pharmacol; 2019 Oct; 59(10):1366-1378. PubMed ID: 31012984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants.
    Bundrant L; Hunt TL; Banks P; Gopinathan S; Boehm KA; Kassler-Taub K; Tyle P; Wilson A; Warner C; Wason S
    Clin Ther; 2021 Jun; 43(6):1029-1050. PubMed ID: 34108079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
    Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
    Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study.
    Zhu X; Wu M; Wang H; Li H; Lin J; Peng Y; Hu Y; Li C; Ding Y
    Expert Opin Investig Drugs; 2021 May; 30(5):579-589. PubMed ID: 33682556
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects.
    Danto SI; Shojaee N; Singh RSP; Li C; Gilbert SA; Manukyan Z; Kilty I
    Arthritis Res Ther; 2019 Dec; 21(1):269. PubMed ID: 31805989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, Pharmacokinetics, and Pharmacodynamics of the ADAMTS-5 Inhibitor GLPG1972/S201086 in Healthy Volunteers and Participants With Osteoarthritis of the Knee or Hip.
    van der Aar E; Deckx H; Dupont S; Fieuw A; Delage S; Larsson S; Struglics A; Lohmander LS; Lalande A; Leroux E; Amantini D; Passier P
    Clin Pharmacol Drug Dev; 2022 Jan; 11(1):112-122. PubMed ID: 34859612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of single and multiple doses of a novel mGlu2 agonist, a potential antipsychotic therapy, in healthy subjects.
    McColm J; Brittain C; Suriyapperuma S; Swanson S; Tauscher-Wisniewski S; Foster J; Soon D; Jackson K
    Br J Clin Pharmacol; 2017 Aug; 83(8):1654-1667. PubMed ID: 28156011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The randomized, single- and multiple- ascending dose studies of the safety, tolerability, pharmacokinetics of CSPCHA115 in healthy Chinese subjects.
    Jing S; Liu W; Yang K; Lin Y; Yao X; Sun G
    Clin Transl Sci; 2023 Mar; 16(3):447-458. PubMed ID: 36495036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT
    Nirogi R; Bhyrapuneni G; Muddana NR; Goyal VK; Pandey SK; Mohammed AR; Ravula J; Jetta S; Palacharla VRC
    Clin Drug Investig; 2021 May; 41(5):469-482. PubMed ID: 33788154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Henagliflozin, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter 2, in Healthy Subjects Following Single- and Multiple-dose Administration.
    Zhang YF; Liu YM; Yu C; Wang YT; Zhan Y; Liu HY; Zou JJ; Jia JY; Chen Q; Zhong DF
    Clin Ther; 2021 Feb; 43(2):396-409. PubMed ID: 33454124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.